Relief Therapeutics completes strategic transition with sale of MOST US rights By Investing.com
Sale of GOLICA ® Nutrisens rights outside the US
Facility to focus on research and development of pipeline assets and licensing for commercialized products
GENEVA, SWITZERLAND / ACCESS Newswire / January 22, 2025 / RELIEF THERAPEUTICS Holding SA(SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief or the Company), a biopharmaceutical company dedicated to providing innovative treatment options for select specialty, unknown and rare diseases, today announced the sale of its intellectual property rights and commercialization for GOLIKE outside the United States to Nutrisense, a leading independent platform that develops and commercializes clinical nutrition solutions for patients. This transaction completes Relief’s previously announced transition from a direct marketing and sales infrastructure to a partnership-based model, allowing the company to optimize its cost structure and allocate resources to advance its high-priority research and development programs.
According to the contract, Nutrisens will take over marketing and sales activities for GOLIKE in Relief’s European markets. Relief also transferred its existing third-party distribution agreements for GOLIKE in other regions to Nutrisens, while retaining its rights in the United States, where the product is exclusively licensed to Eton Pharmaceuticals (NASDAQ:). With its significant experience, Nutrisens will continue to support patients and healthcare professionals with GOLIKE solutions worldwide outside of the United States. Relief intends to continue to supply GOLIKE globally and complete the development of certain line extensions to meet patient needs.
“Over the past year, we have progressively transformed our organization to build on our strengths in drug development and commercialization of our products across businesses,” said Dr. Raghuram Selvaraju, chairman of Relief’s board of directors. “This strategic transformation has refocused our efforts on developing innovative treatments, streamlined operations and improved our ability to serve patients. We are well-positioned to continue advancing our programs in rare dermatology and metabolic disorders, while simultaneously continuing to explore potential pipeline expansion into gastrointestinal therapeutic space through our ongoing discussions with Renexxion.”
Relief has received CHF 1.2 million upfront from Nutrisens and is entitled to certain contingent payments. Following this payout, Relief reported a cash balance of CHF 15.3 million as of January 22, 2025, securing its ability to achieve key near-term R&D milestones and advance its strategic goals.
O GOLIKES ®
GOLIKE products are Foods for Special Medical (TASE:) Purposes (FSMP) developed by Relief with sustained-release formulations that closely replicate the physiological absorption of amino acids found in natural proteins. By masking the unpleasant taste and odor commonly associated with amino acids, GOLIKE offers a more palatable, more patient-friendly solution that addresses key challenges in nutritional management. The GOLIKE product line includes PKU GOLIKE, designed for the dietary treatment of phenylketonuria, as well as additional products currently in development.
ABOUT RELIEF
Relief is a commercial biopharmaceutical company dedicated to advancing treatment paradigms and delivering improvements in efficacy, safety and convenience to the well-being of patients living with select specialty and rare diseases. Relief’s portfolio offers a balanced mix of revenue-generating marketed products, proprietary, globally patented TEHCLO™ and Physiomimic™ platform technologies, and a targeted clinical development pipeline consisting of risk-reducing agents targeting three key therapeutic areas: rare skin diseases, rare metabolic disorders and rare respiratory diseases. In addition, Relief commercializes several legacy products through licensing and distribution partners. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and is listed in the US on the OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.
CONTACT:
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
WAIVER
This press release contains forward-looking statements that may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics and other risks or changes in circumstances. This communication is available as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: Relief Therapeutics Holding SA
View the original press release on ACCESS Newswire
